Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

BACKGROUND Long-term survival from Hodgkin lymphoma (HL) is 80-90%, but the treatment has serious late adverse effects. Modern risk-adapted treatment requires accurate assessment of the patient's prognosis. This investigation assessed the value of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two or three cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS A total of 85 patients with HL underwent FDG-PET after two or three cycles of chemotherapy. Median follow-up was 3.3 years. FDG-PET results were related to PFS and OS using Kaplan-Meier analysis. Regression analyses were employed to test for independence of established pretreatment prognostic factors. RESULTS After two or three cycles of chemotherapy, 63 patients had negative FDG-PET scans, nine patients had minimal residual uptake (MRU) and 13 patients had positive scans. Three PET-negative patients and one patient from the MRU group relapsed. In the PET-positive group, nine patients progressed and two died. Survival analyses showed highly significant associations between early interim FDG-PET and PFS (P <0.0001) and OS (P <0.03). All advanced-stage patients with positive interim FDG-PET relapsed within 2 years. CONCLUSION Early interim FDG-PET is an accurate and independent predictor of PFS and OS in HL. A positive interim FDG-PET is highly predictive of relapse in advanced-stage disease.

[1]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  V. Diehl,et al.  [Hodgkin's disease]. , 1996, Revue medicale suisse.

[3]  L. Specht,et al.  FDG-PET in the clinical management of Hodgkin lymphoma. , 2004, Critical reviews in oncology/hematology.

[4]  M. Cowles.  Modelling Survival Data in Medical Research (2nd ed.) (Book) , 2004 .

[5]  A. D. Van den Abbeele,et al.  FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison , 2004, Leukemia & lymphoma.

[6]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.

[7]  J. Sweetenham,et al.  Current therapies in Hodgkin's disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  B Beuthien-Baumann,et al.  Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[12]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[13]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. , 2001, Haematologica.

[14]  B. Krug,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease , 2001, Annals of Hematology.

[15]  S. Hain,et al.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[17]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[18]  N. Schmitz,et al.  High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation , 1999 .

[19]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[20]  R Peto,et al.  Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Horning,et al.  Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. , 1997, Blood.

[22]  R. Hoppe.  Hodgkin's disease: complications of therapy and excess mortality. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Brian Everitt,et al.  A Handbook of Statistical Analyses Using SPSS , 2003 .

[25]  Hancock,et al.  Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease. , 1996, Seminars in radiation oncology.

[26]  O. Hoekstra,et al.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  A G Stansfeld,et al.  Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[29]  J. Connors,et al.  Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. , 1991, Blood.

[30]  M. Henry-Amar,et al.  Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. , 1990, Seminars in oncology.

[31]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.